SRT Versus SRT+ADT in Prostate Cancer

Inclusion Criteria: * Histological confirmation of prostate acinar adenocarcinoma with a minimum of 10 biopsy cores taken * Prostate protocol MRI for local staging * Patients belonging to intermediate unfavorable group according to the D'Amico/NCCN risk group classification: * -Grade group 3 or/and * -2-3 risk factors for intermediate category (PSA 10-20 ng/ml/ Grade group 2-3/ cT2b cT2c) or/and * -biopsy cores positive ≥50% * Patients belonging to a subclass of high risk group according to the D'Amico/NCCN risk group classification: * -ISUP group 4 (GS 4+4, 3+5, 5+3) or * -cT3a stage or * PSA\>20 * Eastern Coooperative Oncology Group (ECOG) PS 0-2 * Ability of the patient to understand and sign a written informed consent document * Ability and willingness to comply with patients reported outcome questionnaires schedule during the study time * IPSS 0-15 * Prostate Volume less than 100cc * PSA must be dosed maximum 60 days before randomization * No pathologic lymph nodes and distant metastasis on PET (fluorocholine) scan or CT scan+bone scan. * Contraceptive measures for patients with partners with reproductive potential must be explained Exclusion Criteria: * History of Malignant tumors in the previous 2 years excluding non melanoma cancers of the skin. If a patient presents an anamnesis of malignancy (excluding non melanoma skin cancers) it must be free from disease since 24 months at the time of enrollement. * Previous prostate surgery other than TURP (at least 6 weeks prior to start of SBRT). * Previous pelvic RT * Prior androgen deprivation therapy (excluding 5alpha reductase inhibitors) * Any prior active treatment for prostate cancer; patients on previous active surveillance are eligible if inclusion criteria are met * Active severe inflammatory bowel disease * Bilateral hip prothesis or any implant that could seriously interfere with dosimetric calculations * Age \>80 years. * cT4a, cT3b or pelvic lymph node involvement * Controindication or hypersensitivity to the use of Triptoreline * 5alpha reductase inhibitors not discontinued 4 weeks prior to randomization * History of bone fractures and fall * Risk factors for abnormal heart rhythms or QT prolongation. * Use of concomitant medications that prolong the QT/QTc interval